DEF 14A: Tandem Diabetes Care Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Tandem Diabetes Care will hold its 2025 Annual Meeting of Stockholders virtually on May 21, 2025, to vote on the election of directors, executive compensation, the frequency of say-on-pay votes, and the ratification of the company's independent auditor.

Summary

• Tandem Diabetes Care will host its 2025 Annual Meeting of Stockholders virtually on May 21, 2025, at 3:00 p.m. Pacific Time.
• Stockholders will vote on electing eight directors for a one-year term, approving executive compensation on an advisory basis, determining the frequency of future say-on-pay votes, and ratifying the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025.
• The board recommends voting for all director nominees, approving executive compensation, selecting a one-year frequency for say-on-pay votes, and ratifying the auditor appointment.
• In 2024, Tandem Diabetes Care achieved approximately $940 million in worldwide sales and grew its worldwide customer base by approximately 7% to more than 480,000 customers.
• The company launched Tandem Mobi with Dexcom G7 integration and grew its shipments throughout 2024.
• The company also achieved a double-digit increase in people converting from multiple daily injections in the United States.
• The company signed pharmacy agreements for Tandem Mobi covering approximately 20% of U.S. lives.
• The company received FDA clearance to market Control-IQ+ technology to people living with type 2 diabetes in the United States.
• The company's executive compensation program is designed to attract, retain, and motivate talented executives while aligning their interests with those of stockholders.
• The company's executive compensation program includes base salary, short-term cash incentives, long-term equity incentives, and other benefits.
• The company's short-term cash incentive program rewards executives for achieving pre-established financial and strategic goals.
• The company's long-term equity incentive program aligns the interests of executives with those of stockholders by tying a meaningful portion of total compensation to increases in the value of the company.
• The company's board of directors has adopted stock ownership guidelines for executive officers and directors to align their interests with those of stockholders.
• The company's board of directors has adopted a clawback policy to recover incentive compensation paid to executive officers and certain other employees in the event of an accounting restatement due to fraud or intentional misconduct.
• The company's board of directors has approved employment severance agreements with all of its senior management personnel, including each of its NEOs.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook for Tandem Diabetes Care, highlighting record sales, customer base growth, and product launches. However, the document also acknowledges the competitive environment and the need to navigate operational and commercial risks.

Positives

• The company achieved record sales both in the United States and internationally.
• The company grew its worldwide in-warranty installed base to more than 480,000 customers.
• The company launched Tandem Mobi with Dexcom G7 continuous glucose monitoring (CGM) integration and grew its shipments quarter-over-quarter throughout 2024.
• The company grew the United States insulin pump market by achieving a double-digit increase in people converting from multiple daily injections.
• The company signed pharmacy agreements for Tandem Mobi covering approximately 20% of U.S. lives.
• The company received U.S. Food and Drug Administration (U.S. FDA) clearance to market Control-IQ+ technology to people living with type 2 diabetes in the United States.
• The company's executive compensation program is designed to attract, retain, and motivate talented executives while aligning their interests with those of stockholders.
• The company's board of directors has adopted stock ownership guidelines for executive officers and directors to align their interests with those of stockholders.
• The company's board of directors has adopted a clawback policy to recover incentive compensation paid to executive officers and certain other employees in the event of an accounting restatement due to fraud or intentional misconduct.

Negatives

• The company's NEOs were awarded cash bonuses at 89.5% of target, indicating that the company did not fully achieve its financial performance objectives, product development achievements and customer satisfaction scores compared to objectives set at the beginning of 2024.

Risks

• The company faces risks relating to its business, operations, strategic direction and regulatory environment, as well as legal, financial, compliance, liability, information technology, human capital management, compensation, cybersecurity, environmental, social, governance, and reputational risks.
• The company is continuing to assess and respond to the substantial operational and commercial risks relating to the growth of its business operations while also navigating impacts related to intensifying competition and global macroeconomic conditions.

Future Outlook

The company is focused on building and preparing for the future as it executes on multiple strategic initiatives, including expanding its multi-channel durable medical equipment and pharmacy strategy for Tandem Mobi and implementing operational efficiencies to set the stage for sustained profitability in 2025 and beyond.

Industry Context

The company operates in the competitive medical device and technology industries, particularly in the diabetes care market. The announcement highlights the company's efforts to expand its product portfolio, increase its customer base, and improve its financial performance in this environment.

Comparison to Industry Standards

• The document mentions benchmarking executive compensation against a peer group of companies in the healthcare equipment and healthcare services industries.
• The peer group includes companies such as AngioDynamics, Glaukos, Insulet, Dexcom, and Masimo.
• The company aims to align its executive compensation with the 50th percentile of its peer group, reflecting a commitment to market competitiveness.
• The company's three-year average burn rate was 3.0% calculated in accordance with the value adjusted burn rate methodology.

Management Changes

Corporate Governance

Legal Proceedings

• There are no legal proceedings related to any of the directors, director nominees, or executive officers which require disclosure pursuant to applicable SEC rules.

Related Party Transactions

• Mr. Sheridan, our President and Chief Executive Officer and a member of our board of directors, and Ms. Vosseller, our Executive Vice President, Chief Financial Officer and Treasurer, are involved in a personal relationship and share a primary residence.
• Mr. Twomey, a member of our board of directors, is the brother-in-law of one of our employees who is a manufacturing engineer whom we have employed since August 2019.

Stakeholder Impact

• The company's performance and strategic initiatives may impact key stakeholders such as shareholders, employees, customers, suppliers, and creditors.
• The company's commitment to environmental, social, and governance priorities may impact stakeholders such as the community, the environment, and future generations.

Next Steps

• Stockholders are encouraged to read the proxy statement and submit their proxy or voting instructions as soon as possible.
• The company will publish final voting results in a Current Report on Form 8-K within four business days following the Annual Meeting.

Key Dates

Keywords

Tandem Diabetes Care, Annual Meeting, Stockholders, Directors, Executive Compensation, Say-on-Pay, Auditor, Ernst & Young, Proxy Statement, Compensation, Governance, Insulin Pump, Diabetes, Medical Device